Both clinical and molecular evidence suggest that canine OSA exhibits a similar biology to its human counterpart including anatomic location, presence of early microscopic metastatic disease at diagnosis, development of chemotherapy-resistant metastases, altered expression/activation of several proteins (e.g. Met, PTEN, STAT3), and p53 inactivation, among others [2, 4]. Here, MET is linked to obstructive sleep apnea syndrome.